(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 1.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Moderna's revenue in 2024 is $6,848,000,000.On average, 10 Wall Street analysts forecast MRNA's revenue for 2024 to be $1,586,978,512,602, with the lowest MRNA revenue forecast at $1,425,285,895,123, and the highest MRNA revenue forecast at $1,808,963,810,597. On average, 10 Wall Street analysts forecast MRNA's revenue for 2025 to be $1,959,271,410,624, with the lowest MRNA revenue forecast at $1,549,857,043,860, and the highest MRNA revenue forecast at $2,776,182,136,649.
In 2026, MRNA is forecast to generate $2,912,137,920,764 in revenue, with the lowest revenue forecast at $1,499,602,954,811 and the highest revenue forecast at $6,130,173,585,756.